Join us at CVCF 2026 to explore how startups can scale and win in the age of AI.
Updated
October 28, 2026 6:18 PM
CVCF 2026 takes place on 4–5 November at Cyberport, Hong Kong. IMAGE: CYBERPORT
AI can help you build a startup, but it won’t automatically make you stand out. When everyone has access to similar tools, you need to give customers a reason to choose you and investors a reason to back you. So, how do you turn innovation into a competitive edge?
That question sits at the heart of Cyberport Venture & Capital Forum (CVCF) 2026, taking place on 4–5 November under the theme “Scaling in a Changing World: Winning the Next Competitive Cycle” and the message “Scale Up & Win.”
The two-day forum will feature more than 80 speakers discussing venture investment, AI-driven growth, emerging technologies and expansion into new markets. Day 1 will explore global investment trends and the next wave of innovation. Day 2 will feature CVCF 2026’s spotlight event, the Agentic Economy Summit, examining how agentic AI and digital assets could reshape business and finance. The wider programme will also include investor matching, founder pitches, 100+ Innovator Showcase, startup workshops and clinics.
With founders and investors navigating a fast-changing technology landscape, CVCF 2026 will explore what it takes to stay competitive, scale into new markets and turn emerging opportunities into business growth. Here’s a look at the key programmes lined up for this year’s forum.
CVCF 2026 will explore investment trends, global expansion, AI and digital assets. IMAGE: CYBERPORT
Keynotes and Panels: Finding the Next Big Opportunity
Taara founder and CEO Mahesh Krishnaswamy will deliver the keynote The Innovation Playbook: Capitalizing on Moonshots and Faster Cycles in the Age of AI. The wider Day 1 programme will cover global investment trends, expansion into new markets, agentic AI and one-person companies.
For startups navigating the AI market, the panel Mastering the AI Bubble: Capital Rerouting and How Global Champions Stand Out will bring together panellists from Quona Capital, Alumni Ventures, FOV Ventures and Capital6 to discuss how investors assess startups and distinguish commercial potential from market hype. Other sessions will explore emerging technologies beyond AI software, including embodied AI, advanced computing and commercial aerospace.
Investor Matching and Networking: Connecting with Capital
Away from the conference sessions, MatchEasy will help founders and investors arrange one-to-one meetings, either onsite or online. Confirmed participants will receive access to the platform to explore potential matches and schedule meetings.
Investors can also discover local and international startups through the Founder Pitch programme, where entrepreneurs present their projects and ventures. Meanwhile, the Innovator Showcase offers a separate opportunity to explore emerging technology solutions through a virtual platform and selected on-site exhibits.
For founders seeking more tailored guidance, the Startup Clinics will offer one-to-one discussions with industry experts and experienced entrepreneurs on business challenges, fundraising and growth. Advance registration is required.
Hands-On Workshops: Strengthening Your Investment Pitch
Turning an innovative idea into a business that investors can back takes more than a strong pitch. CVCF 2026 will host practical workshops to help founders strengthen their fundraising strategies and make a stronger case to investors.
Led by Capital6 advisor Christine Keung, one workshop will explore how founders can align technical innovation with business goals, communicate their product’s value and prepare for fundraising. Another, led by Jeremy Dalton, advisor at FOV Ventures and SXSW Pitch, will help founders understand how investors assess startups, with opportunities to pitch live and receive direct feedback.
CVCF 2026’s spotlight event, the Agentic Economy Summit, will take place on 5 November under the theme “Intelligent Frontiers, Tokenised Horizons: Where Agentic AI Reshapes Business and Digital Assets Redefine How Value Moves.”
The summit will bring together technology and finance leaders to explore how agentic AI and digital assets could change the way businesses operate. Wolf Ruzicka, chief commercial officer at Unlimit, a global payments company, will discuss building and scaling agentic AI applications. Dr Feng Xiao, chairman and CEO of HashKey Group, will examine how digital identity, tokenised assets and money connect on-chain.
The discussions will also look at agent-led commerce, including how AI agents could help customers choose products and make purchases, and the payment systems needed to support these transactions. Other topics include Hong Kong dollar stablecoins and their potential role in payments and settlement, as well as the rise of one-person companies. The summit will also explore how founders can use AI agents to run their businesses with smaller teams, find customers and generate recurring revenue.
From AI-driven growth and cross-border investment to agentic AI and digital assets, CVCF 2026 brings together the people and ideas shaping the next phase of business. Whether you're preparing to raise capital, exploring new markets or assessing emerging technologies, the forum offers an opportunity to gain fresh perspectives and connect with investors, founders and industry leaders.
Exclusive for Ventureport readers: Use the promotional code cvcf26vp to access a Full Access Pass for HK$300, subject to confirmation of the offer by the organiser.
Date: 4–5 November 2026
Function Rooms, Level 3, Core E, Cyberport 3, Hong Kong
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
August 10, 2026 5:56 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.